Business Wire

RevBio Receives Approval to Start a Dental Clinical Trial in Italy for its Regenerative Biomaterial

Share

RevBio, Inc., announced that it has received approval from the Italian Ministry of Health and the Ethics Committee of the University “G.D'Annunzio” of Chieti-Pescara to start a 15-patient pilot clinical trial. The primary objective of this study will be to assess the time it takes for Tetranite®, the company’s adhesive biomaterial, to regenerate bone in the mandibular and maxillary dental arches.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230117006135/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Prior studies have demonstrated that TETRANITE® is replaced with bone via substitution as it dissolves, stimulating osteoblast cells to produce osteoid (bone precursor) which is then mineralized during the process of bone maturation. (Graphic: Business Wire)

This study will be conducted at the Center for Advanced Studies and Technology (“CAST”) of the University “G.d’Annunzio” Chieti-Pescara under the leadership of Professor Sergio Caputi, MD, DDS, who serves as the Chancellor/Provost of the University. The research team also includes Professor Maurizio Piattelli, MD, DDS, Tonino Traini, DDS, PhD, Bruna Sinjari, DDS, PhD, Gianmaria D’Addazio, DDS, PhD, and Manlio Santilli, DDS, PhD Student. This team is part of the Department of Innovative Technologies in Medicine and Dentistry where novel and cutting-edge research in dentistry is conducted.

“We are very pleased to see this study come together after much planning during the COVID-19 pandemic,” said Dr. Sinjari. “We have assembled a great research team which will be able to assess the unique osteoconductive properties of this biomaterial.”

Currently there are no products approved in Europe or the United States that are adhesive to bone and capable of bonding dental implants into place while gradually resorbing and being replaced by new, native bone. These properties have been demonstrated in prior studies, but the focus of this study will be to assess the timescale when the material is resorbed by the human body, which will help determine the length of future clinical trials necessary for obtaining commercial approval.

Dr. Paul Fugazzotto, DDS, an advisor to RevBio, and a noted lecturer, dental educator, and periodontist, introduced the company to the research team at the University of Chieti. “The design of this study will answer some important questions that will help evidence the key advantages of this biomaterial,” said Dr. Fugazzotto. “I believe this technology will be transformative in the way we place dental implants.”

About RevBio, Inc.

RevBio, Inc., is a clinical stage medical device company engaged in the development and commercialization of a patented, synthetic, injectable, self-setting, and osteoconductive bone adhesive biomaterial called Tetranite®. The company is initially developing this technology for use in the dental, cranial, and broader orthopaedic markets as well as applications in the animal health market. RevBio's Tetranite technology is not yet approved for commercial use.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Michael Tiedemann
mtiedemann@revbio.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Wolters Kluwer named Market Leader in BARC Score Financial Performance Management 202428.3.2024 12:09:00 CET | Press release

Wolters Kluwer, a global leader in information, software, and services for professionals, today announces that its CCH® Tagetik expert solution has retained its leadership position for the seventh consecutive year in both the Global and DACH region issues of the prestigious BARC Score Financial Performance Management (FPM) Report. Developed by BARC, one of Europe’s leading analyst firms for business software, the reports highlight CCH Tagetik’s strength as a unified platform for financial corporate management (financial consolidation and close; budgeting, planning, and forecasting; ESG and regulatory reporting; corporate tax) that can be used by individual subsidiaries or at group level. Ralf Gärtner, Senior Vice President and General Manager of Corporate Performance & ESG, Wolters Kluwer, said: “The BARC Score FPM Reports have ranked CCH Tagetik as a market leader year after year, recognizing our consistent commitment to product excellence and innovation. We are focused on empowering

Cirium’s Airfare Data Shows Increases in Economy Airfares in 2023 in North America and Europe With a Decrease in Transatlantic Business Class Fares28.3.2024 11:37:00 CET | Press release

Cirium, the leading aviation analytics company, analysed airfare trends for 2023, using Cirium FM Traffic. Economy airfare has generally increased since 2023 in North America and Europe, but lower than the U.S. inflation rate. “While airfare has risen in nominal terms in U.S. and Europe, consumers will appreciate that the increases are less than other consumables,” said Jeremy Bowen, CEO of Cirium. “Cirium’s data teams will continue to monitor the impact on fares of increased capacity in the market, despite challenges related to the availability of aircraft, be it due to groundings, engine issues, or supply chain constraints.” Cirium analysed airfare for the U.S. domestic market (including 13 U.S. airlines), intra-European travel, and the Transatlantic market. The data is non-directionally averaged, in U.S. dollars, not including taxes and fees. Unless otherwise noted, the fares indicated are for economy class. U.S. Domestic Airfare The average U.S. domestic airfare by the 13 airlines

Ministry of Education and Science of Ukraine and Palantir Partner to Create Safe Conditions for In-Person Education in Schools28.3.2024 10:00:00 CET | Press release

The Ministry of Education and Science, along with Palantir (NYSE:PLTR), a leading provider of AI systems, have signed an agreement. The main goal is to facilitate qualitative transformations in the field of education and ensure the maximum number of children have access to safe in-person learning. The agreement, initially for 12 months, will support the Government’s official School Offline initiative which aims to provide 300,000 more Ukrainian pupils with safe access to a school. New software tooling will enable: Funding allocated for school bomb shelters to be targeted where it will deliver the greatest benefit for children and young people of a school age. Every school to receive a risk rating according to a methodology recently adopted in law as a Cabinet of Ministers decree, in order to help identify targeted measures that will improve the safety of a school. The rating will take into account factors such as historic shelling in the area, presence of a bomb shelter, safety of acce

Guidewire Jasper Release Boosts Commercial Lines Agility for P&C Insurers and Strengthens Functionality Across Entire Product Portfolio28.3.2024 08:05:00 CET | Press release

Guidewire (NYSE: GWRE) announces Jasper, its latest release, which boosts commercial lines agility for P&C insurers with support for layered coinsurance, schedule import, and a new U.S. Bureau Content Solution.* Additionally, expanded HazardHub data for Canada gives insurers deeper property risk insights for underwriting precision. Jasper release will be generally available on April 5, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240328607054/en/ “Commercial lines insurers face both risk and opportunity. On the one hand, there are economic fluctuations, including inflation, geopolitical complexities, capital limitations, and environmental challenges. On the other hand, the protection gap creates growth opportunities for insurers that innovate to stay ahead of the evolving risk landscape,” said Eugene Lee, senior vice president and general manager, InsuranceSuite, Guidewire. For P&C insurers seeking to improve commerc

Surge announces closing of a €7.5 million fundraising round to decrypt the immune system and transform precision medicine28.3.2024 08:00:00 CET | Press release

Surge has just closed its second round of funding, raising €7.5 million. The round was led by Eurazeo with the participation of Kima, Teampact, and MH Innov’, as well as the support of historical funds Boutique Venture, HCVC, and 50 Partners Santé. The fundraising is complemented by grants from BPI, including support for deep tech development and the Future Investment Program, of which Surge was a laureate. This second round of funding, marked by the entry of strategic investors, reflects Surge's accelerated development and the beginning of the commercial expansion phase. This funding will enable the opening of SurgeLab™, a premier laboratory dedicated to the discovery of immune biomarkers, and the finalization of PreCyte®'s industrialization. It will also support the refinement of its cutting-edge AI algorithms. "Building on solid scientific and technical fundamentals, Surge has already demonstrated the relevance of its biomarker discovery platform to address concrete clinical needs a

HiddenA line styled icon from Orion Icon Library.Eye